Click Complete Post Test to answer multiple choice questions
With advances in genetic testing technology, it is possible to more accurately diagnose monogenic diabetes and provide individualized treatment for non-obese diabetic patients (Murphy et al., 2023)
Prior to Wegovys FDA approval for obesity, there were approximately 190,000 approved claims for GLP-1 medications to treat obesity each month
However, these agents can be expensive for patients whose insurances do not cover the medications
The 2 mg pen the highest available dose, prescribed for patients who require additional glycaemic control beyond 1 mg
With insurance, oral Wegovy can cost more, less, or the same, depending on your coverage and eligibility for any savings offers